Drugs / ABI-2280
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05502367 | Sep 2022 → Oct 2025 | cervical intraepithelial neoplasia | Antiva Biosciences | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06491446 Comparator | Mar 2024 → Oct 2025 overdue | human papilloma virus infection | Antiva Biosciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-2280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06491446 ↗ |
| Route | Other | “ABI-2280 Vaginal Tablet/Insert” NCT05502367 ↗ |